Advancements in Clinical Applications of Immune Checkpoint Inhibitors
A special issue of Reports (ISSN 2571-841X).
Deadline for manuscript submissions: closed (30 November 2024) | Viewed by 993
Special Issue Editors
Interests: HIV; infection
Special Issues, Collections and Topics in MDPI journals
Interests: epigenetics; DNA demethylation; ubiquitin ligase; gynecologic oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
It has been more than ten years since the clinical use of immune checkpoint inhibitors (ICIs), and we are still trying to utilize them more effectively.
This Special Issue aims to compile a collection of articles that highlight the latest advancements in the clinical research of immune checkpoint inhibitors, including but not limited to the following:
- Clinical trials evaluating the efficacy and safety of immune checkpoint inhibitors in different cancer types.
- Combination therapies involving immune checkpoint inhibitors.
- Management of adverse events related to immune checkpoint inhibitors.
- Biomarkers related to immune checkpoint inhibitor therapy.
- Timing to stop ICIs.
We invite the submission of original research articles, reviews, and case reports in this field.
Dr. Yugo Ashino
Dr. Ichiro Onoyama
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Reports is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immune checkpoint inhibitors
- immune checkpoints
- immunotherapy
- combination therapies
- immune-related adverse events (irAEs) and treatment-related adverse events (TRAEs)
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
